Phase III Trial of TR115 vs Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
A Phase III trial is underway to evaluate TR115, an EZH2 inhibitor, against standard treatments in relapsed/refractory peripheral T/NK-cell lymphoma.